2,5-二氯-N-(2-甲基-4-硝基苯基)苯磺酰胺
| 中文名称 | 2,5-二氯-N-(2-甲基-4-硝基苯基)苯磺酰胺 |
|---|---|
| 中文同义词 | 2,5-二氯-N-(2-甲基-4-硝基苯基)苯磺酰胺;WNT/BETA-CATENIN和PPAR信号通路抑制剂(FH535);FH535, 一种WNT/Β-CATENIN和PPAR信号传导抑制剂;化合物FH535;Β-连环蛋白/TCF 抑制剂, FH535 CALBIOCHEM |
| 英文名称 | FH 535 |
| 英文同义词 | β-Catenin/Tcf Inhibitor, FH535;FH 535(FH-535);FH535;FH 535;FH-535;FH 535;N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonaMide;2,5-Dichloro-N-(2-Methyl-4-nitrophenyl)benzenesulfonaMide;2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide FH535;β-Catenin/Tcf Inhibitor, FH535 - CAS 108409-83-2 - Calbiochem |
| CAS号 | 108409-83-2 |
| 分子式 | C13H10Cl2N2O4S |
| 分子量 | 361.2 |
| EINECS号 | |
| 相关类别 | 小分子抑制剂;小分子抑制剂，天然产物;细胞生物学试剂;API;Aromatics;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol文件 | 108409-83-2.mol |
| 结构式 |  |
2,5-二氯-N-(2-甲基-4-硝基苯基)苯磺酰胺 性质
| 熔点 | 141-142℃ |
|---|---|
| 沸点 | 526.3±60.0 °C(Predicted) |
| 密度 | 1.566±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO: soluble20mg/mL |
| 形态 | Yellow solid |
| 酸度系数(pKa) | 5.83±0.10(Predicted) |
| 颜色 | Tan |
| 稳定性 | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
| InChIKey | AXNUEXXEQGQWPA-UHFFFAOYSA-N |
|
PPAR
|
Wnt
|
β-catenin
|
FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth. FH535 represses angiogenesis-related genes in pancreatic cancer cells.
FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts.